Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139147 | 0.92 | ALDH1A1 (0.41) | KMT2AMEN1SMN1; SMN2SPRALDH1A1 | |
| SCHEMBL2586402 | 0.92 | KMT2A (0.42) | KMT2AMEN1ALDH1A1XBP1HTT | |
| SCHEMBL4789205 | 0.92 | KMT2A (0.42) | KMT2AMEN1ALDH1A1XBP1HTT | |
| SCHEMBL778489 | 0.91 | ALDH1A1 (0.39) | KMT2AMEN1SPRALDH1A1XBP1 | |
| SCHEMBL15049603 | 0.84 | ALDH1A1 (0.39) | KMT2AMEN1SPRALDH1A1XBP1 | |
| SCHEMBL775883 | 0.83 | HTT (0.41) | KMT2AMEN1SMN1; SMN2SPRALDH1A1 | |
| SCHEMBL4759981 | 0.83 | HTT (0.41) | KMT2AMEN1SMN1; SMN2SPRALDH1A1 | |
| SCHEMBL2578184 | 0.81 | SPR (0.40) | KMT2AMEN1SMN1; SMN2SPRALDH1A1 | |
| SCHEMBL2584875 | 0.81 | ALDH1A1 (0.38) | KMT2AMEN1SMN1; SMN2SPRALDH1A1 | |
| SCHEMBL122901 | 0.78 | GAA (0.40) | KMT2AMEN1SMN1; SMN2SPRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586611-B2 | Fungicidal carboxamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1948649-B1 | FUNGICIDAL CARBOXAMIDES | DU PONT (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20110269712-A1 | Fungicidal Carboxamides | BISAHA JOHN JOSEPH | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269712-A1 | Fungicidal Carboxamides | NAT1, PFAS, CHRM1 | KMT2A 404/4885MEN1 773/4885SMN1; SMN2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.